Posted by Michael Wonder on 12 Dec 2023
PHARMAC proposes to fund treatments for breast and blood cancer
12 December 2023 - PHARMAC is seeking feedback on a proposal to fund two new treatments for advanced breast cancer and a type of blood cancer.
The treatments, ribociclib (branded as Kisqali) and midostaurin (branded as Rydapt), are part of a bundle deal with the supplier, Novartis.
